3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
55
Neoplasms
15
Sarcoma
12
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
5
Unspecified Adult Solid Tumor, Protocol Specific
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Liposarcoma
2
Leiomyosarcoma
2
Carcinoma
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Salivary Gland Neoplasms
1
Relapsed Solid Tumors
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurotoxicity Syndromes
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Lymphoma
1
Interventions
Cyclophosphamide
282
Rituximab
260
Etoposide
161
Filgrastim
155
Vincristine
145
Doxorubicin
134
Prednisone
117
Cytarabine
108
Radiotherapy
102
Peripheral Blood Stem Cell Transplantation
90
Methotrexate
90
fludarabine phosphate
87
Melphalan
78
Busulfan
71
Dexamethasone
59
Granulocyte Colony-Stimulating Factor
56
Carmustine
53
fludarabine
51
Bortezomib
46
Tacrolimus
44
Mycophenolic Acid
41
Antilymphocyte Serum
41
Ifosfamide
40
Leucovorin
39
Gemcitabine
38
Whole-Body Irradiation
36
Cyclosporine
35
Bendamustine Hydrochloride
34
sargramostim
33
Methylprednisolone
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma
×
eribulin
×
Clear all
NCT02171260
2019-01-15
BOLD 113
Eisai Inc.
Phase 1
Completed
23 enrolled
22 charts